Clinical Trial Update: A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating long-term safety and clinical activity of givosiran (ALN-AS1) in patients with acute intermittent porphyria has completed Phase 1/2 with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Porphyria

Drugs mentioned

• givosiran (givosiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Acute Intermittent Porphyria | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-12